AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer
Biochemical Pharmacology · 2026
DOI: 10.1016/j.bcp.2026.118486 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Wenlong Wan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Interleukin-17, Drug Resistance, Neoplasm, Immunotherapy. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Science and Technology of Hubei Province, Hubei Province Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Given the persistently poor five-year survival rate (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
- Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. Electronic address: miaojianping888@tjh.tjmu.edu.cn.
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. Electronic address: zhaoben@tjh.tjmu.edu.cn.
Förderung
- Department of Science and Technology of Hubei Province
- Hubei Province Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Wan, W., Wei, F., Yang, L., Yu, X., Wang, Z., Miao, J., & Zhao, B. (2026). AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.118486
Vancouver
Wan W, Wei F, Yang L, Yu X, Wang Z, Miao J, et al. AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.118486
BibTeX
@article{Wan2026,
author = {Wan, Wenlong and Wei, Fang and Yang, Lu and Yu, Xiao and Wang, Ziqi and Miao, Jianping and Zhao, Ben},
title = {AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer},
journal = {Biochemical Pharmacology},
year = {2026},
doi = {10.1016/j.bcp.2026.118486}
}
EUVIMED